Saol Therapeutics

About

Saol Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2015. Based in Roswell, Georgia, the company specializes in developing therapies for patients with unmet medical needs, particularly in the areas of central nervous system (CNS) disorders and rare or orphan diseases. Saol has grown to nearly 100 employees and has a strong focus on advancing clinical development. The company is currently engaged in three late-stage clinical trials, including a novel agent with potential applications in pain management and CNS conditions. Saol's pipeline features two Phase 2 trials and a Phase 3 trial targeting an ultra-orphan patient population. In addition to its internal development efforts, Saol seeks to acquire approved prescription products and clinical compounds, forming strategic partnerships with pharmaceutical and biotechnology companies as well as academic institutions.